The success of DNA vaccines in human clinical trials to fight against Covid-۱۹

Recent advances in biotechnology have revolutionized medicine and offered pioneering solutions to unmet clinical needs. Vaccines are one of the most important medical interventions. DNA vaccines addresses many of features of a good vaccine platform such as rapidly simple development, reproducibility, thermostability, and manufacturing with reducing development costs and risks. The global vaccine research and development (R&D) for the pandemic COVID-۱۹ is unprecedented in scale and speed. Due to the need for speed, vaccine designers and developers are making a fundamental change in the vaccine production process, which previously took more than ۱۰ years. Although DNA vaccines have a new platform technology that was not previously available on the market for human use, they are very promising in the SARS-CoV-۲ vaccine race. DNA vaccines can be designed and produced within days after obtaining the genome sequence of the pathogen or nucleotide sequence of cancer antigens. Plasmid DNA manufacturing processes allow for scalable manufacture of DNA vaccines, making them ideal for rapid control of newly emerging pathogens, which circumvent the problems of conventional vaccines produced in eggs or eukaryotic cell culture bioreactors. Here, we summarize the recent clinical trials of DNA vaccines for coronavirus disease ۲۰۱۹ (COVID-۱۹) disease caused by SARS-CoV-۲.

Keywords:

Vaccines , DNA vaccines , nucleic acid vaccines , COVID-۱۹ , SARS-CoV-۲